The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
nice results! The neuroscience digital health company Cambridge Cognition Holdings plc, (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health, today announces its audited preliminary results for the year ended 31 December 2016. Financial Highlights · Total revenues increased by 37% to £6.88m (2015: £5.04m) · Maiden profit for the year of £0.22m (2015: loss of £0.78m*) · Earnings per share of 1.4p (2015: loss of 4.6p*) · Operational cashflow of £0.47m (2015: outflow of £0.71m) · Net cash balances at 31 December 2016 of £2.38m (31 December 2015: £0.76m) · Successful equity placing of £1.25m (£1.14m net proceeds) in April 2016 * Loss in 2015 includes impact of £0.21m one-off exceptional item. There are no exceptional items in 2016. Operational Highlights · Portfolio of products and services expanded to meet needs of wider psychiatric and neurological disease areas · New products to meet the needs of new healthcare economics o More efficient R&D (Recruit product) o Demonstration of treatment benefits (wearable product) · Software and services revenues up 35% to £6.19m (2015: £4.59m) · First contracts won for new wearables and Recruit products · Higher number of new product launches in the year despite lower R&D spend (£0.89m in 2016 compared with £1.30m in 2015) · Commitment made at placing to invest in sales team met and already demonstrating benefits · FDA clearance for CANTAB Mobile enables marketing in the US
results out tomorrow, should see then..
any thoughts on COG?
yes, another big step for us!
nice rns
I wonder too ! ;-)
Grim report on impact of dementia in the UK has been highlighted across the national news today and it emphasised the need for easier testing/monitoring to ease pressure on GP surgeries and improve early interventions Step forward COG one hopes to ease the burden on society and improve quality of life
For COG I wonder?
Easier to read - expanding market as FDA insists on these HAL tests CAMBRIDGE COGNITION CONFIRMS SERIES OF NEW CONTRACTS (ShareCast News) - Neuroscience company Cambridge Cognition Holdings announced a series of new contracts worth more than £0.25m on Thursday, to assess - through CANTAB Connect - the abuse potential of investigational drugs in a new market application for the company. The AIM-traded firm claimed that, since launching its cloud-based CANTAB Connect software platform in 2014, it has become a leading provider of Human Abuse Liability (HAL) assessment technology, helping drug development partners achieve multiple FDA approved abuse deterrent labels. To date Cambridge Cognition has signed 35 HAL contracts following the launch of the CANTAB Connect Abuse Liability product with revenues totalling in excess of £3m in a market which the board expects to continue to grow. The contracts announced on Thursday will use CANTAB Connect to assess abuse potential in a new, unexplored and growing therapeutic area, the board said, which is an extension of the HAL market targeted to date. "Where labour-intensive, imprecise and error-prone manual tests were used previously to measure drug effects, our computerised solutions now improve trial efficiencies and optimise the likelihood of success throughout all stages of drug development," said CEO Steven Powell. "Human abuse liability studies play an increasingly important role in this process and we look forward to supporting new and existing partners and customers through our enlarged commercial team as this market continues to grow."
We use cookies on our website. If you continue to browse our website without taking any action, we will assume that you are happy to receive all cookies from our website.Read More Dismiss FE Trustnet UK | FE Trustnet Offshore | FE Trustnet Hong Kong | FE Trustnet Middle East | FE Analytics | FE Fundlistings rss Rss | About Us | Contact Us | Help logo Company announcementsCompany newsFE Trustnet Fundswire Today's announcementsMost read announcementsAnnouncements archiveAdvanced search Email address Password Register| Login KeywordCompanyEPIC/TIDMSEDOL/ISINNews Price Announcements Fundamentals News Article RSS Cambridge Cognition (COG) Add to Alerts list Print Mail a friend Annual reports Thursday 13 October, 2016 Cambridge Cognition Contract RNS Number : 3877M Cambridge Cognition Holdings PLC 13 October 2016 13 October 2016 Cambridge Cognition Holdings Plc ('Cambridge Cognition' or the 'Company') Contracts signed in new drug development market The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies to facilitate the development of treatments for neurological disorders, today announced a series of new contracts worth over £0.25m to assess, through CANTAB Connect, the abuse potential of investigational drugs in a new market application for the Company. Since launching its cloud-based CANTAB Connect software platform in 2014, Cambridge Cognition has become the leading provider of Human Abuse Liability (HAL) assessment technology1, helping the Company's drug development partners to achieve multiple FDA approved abuse deterrent labels. To date the Company has signed 35 HAL contracts following the launch of the CANTAB Connect Abuse Liability product (vs. 8 before 2014), with revenues totalling in excess of £3m (vs. £0.6m before 2014) in a market which is expected to continue to grow. The abuse of prescription drugs is the fastest growing drug problem in North America. According to the National Institute on Drug Abuse, an estimated 48 million people in the U.S. have used prescription drugs for non-medical reasons. With the rising number of compounds targeting the central nervous system and tighter government regulation in place, clinical trials assessing drug abuse potential are becoming more commonplace and necessary. These HAL trials require more time and resources than most Phase I trials. The CANTAB Connect platform has been used to significantly reduce data errors and increase efficiencies in these studies, saving both time and cost for drug manufacturers. The contracts announced today will use CANTAB Connect to assess abuse potential in a new, unexplored and growing therapeutic area, which is an extension of the HAL market targeted to date. Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition:
Good progress ! Some would say overdue Expect further news flow across the business ie contracts in the "established " areas and the wearable segment which is potentially very exciting Happy to hold and add more
Well LGO.fan, it would be nice if the megadudes liked the look of COG. Why not? The market cap is what they find down the back of the sofa. COG have been in the cognitive test area for 18 years (started when they were part of CeNeS). Technically, academically, they are rock solid. Their advisors are actually the real thing. I believe they can and will do wearables. What's the mass market? Will people want to know how well they are functioning at different times of the day? Maybe. Must be niche areas, e.g. aviation, the military. Might, could, go far.
declaration: so do i :-) Seen brokers forecast increased to 115. More importantly, I am keen to understand what the next big steps are for COG. Any validity in rumours that Apple, Google and Microsoft have an eye on this company?
results out - nice EBITDA losses reduced to £0.11m (H1 2015: £0.26m loss) (More than 50% decrease!) Pharmaceutical clinical trial revenues up 17.3% to £2.24m Commenting on the results Steven Powell, Chief Executive Officer of Cambridge Cognition, said: "The results from the first half of the year reflect the significant advances that have been made in marketing of our core products and technology developments that have resulted in the launch of our online and wearable platforms. Our products and technologies are now aligned with all stages of our customers' drug development cycle and the commercial focus is now set to maximise the opportunities presented by existing sales channels."
First contract signed for patient recruitment product The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies to facilitate early intervention and development of treatments for neurological disorders, today announced that it has secured the first contract for the recently launched CANTAB Recruit product. The drug development industry faces increasing challenges and mounting costs in locating, identifying and recruiting cognitively impaired subjects for clinical trials. This results in expensive recruitment costs and delayed clinical trial completion. Patient recruitment alone amounts to one third of total trial costs1 with 80% of pharmaceutical development programmes being delayed due to unfulfilled enrolment numbers2. CANTAB Recruit is an online patient recruitment product developed and launched by Cambridge Cognition to accelerate the identification of qualified clinical trial participants in high-need neurological indications. By pre-screening subjects remotely with the Company's proprietary CANTAB® cognitive assessments the product is expected to reduce the cost and time of recruitment significantly for drug development companies and research institutes. The first CANTAB Recruit contract has been signed with one of the world's largest biotechnology companies to support its patient enrolment in a late-phase Alzheimer's disease trial, helping to accelerate the development of a new drug treatment. Revenues will be recognised in the current financial year. The commercialisation of CANTAB Recruit represents a significant milestone in the Company's provision of end-to-end neurocognitive services for corporate partners to accelerate the development of optimal treatments from proof of concept to post-marketing. Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition: "As pharmaceutical development moves towards preventative medicine, our customers and partners face a growing challenge to find suitable subjects with neurological disease in the early stages of cognitive decline. CANTAB Recruit will enrich recruitment practices by reducing on-site screen failure rates, saving sponsors substantial time and cost. With the number of drug development programmes in Alzheimer's disease increasing, we forecast that CANTAB Recruit will lead to significant opportunities beyond this initial contract for the Company and its partners."
Hi - like a lot of AIM stuff, volatile. But good potential. This is a small co big in cognition and particularly Alzheimer's. Given there is always interest in dementia, including at the political level, this does give it the possibility to fly. They have good s/w for automating cognitive measurement, and have migrated this to various platforms as they become available, including wearables. I have half a feeling that they will be a takeover candidate from one of the big pharma either to acquire their tech or safely to bury it. Short term, may go to 100 or so. Declaration: I hold shares in this co.
hi guys, am new to this share. any pointers? have a good weekend all
Yes hopefully we will get some contract news and look forward to the results on 22nd.Has risen quite abit since I bought in few weeks ago, seems like a big buyer still working this Will fly on positive news
Came to my attention few weeks ago after big rise. Bought in on dip, hoping for contract news with results on 22nd.
Cambridge Cognition said it is now in discussion with a number of pharmaceutical partners following significant early interest boosted by the results of the study and expects to sign the first Cognition Kit contracts in the near future.
'Lots of talks going on behind close doors.'.....based on?
here today bought in here few weeks ago at a good price.Cog is going to be massive, this share rises on fresh air.Wait till big news arrives, fantastic product which will work with Apple and Microsoft.Lots of talks going on behind close doors.Once people realise the potential here this will boom!!
of course...massive potential...
times